Pancreatic Cancer Research

ResearcherUniversité Paris CitéActive in the last 2 years

Isabelle Trouilloud

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0003-2392-4644; OpenAlex author ID A5058660922. Sources: OpenAlex.

Their work

Papers
19 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
90
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 2 papers · 2015: 3 papers · 2016: 1 paper · 2017: none · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 19

  1. Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of three French multicenter prospective ran… Co-author DOI 10.1016/j.canlet.2026.218745↗
  2. Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study Co-author DOI 10.64898/2026.06.18.26355998↗
  3. Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study. Co-author DOI 10.1093/oncolo/oyaf125↗
  4. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreat… Co-author DOI 10.1200/jco-25-00872↗
  5. Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective… Co-author DOI 10.1016/j.ejca.2024.115051↗
  6. Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo-22-946↗
  7. Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma. Co-author DOI 10.1016/j.clinre.2020.08.016↗
  8. Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. Co-author DOI 10.1016/j.clinre.2020.101607↗
  9. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter … Co-author DOI 10.1016/j.clinre.2019.08.009↗
  10. Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarci… Co-author DOI 10.1016/j.clinre.2019.03.007↗
  11. Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. Co-author DOI 10.1177/1756284819878660↗
  12. [New molecular classification of colorectal cancer, pancreatic cancer and stomach cancer: Towards "à la carte" treatment?]. Co-author DOI 10.1016/j.bulcan.2016.05.007↗
  13. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Co-author DOI 10.1245/s10434-014-3898-9↗
  14. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-… Co-author DOI 10.1245/s10434-015-4783-x↗
  15. Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A… Co-author DOI 10.1371/journal.pone.0125350↗
  16. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastat… Co-author DOI 10.1016/j.ejca.2014.09.015↗
  17. FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study. First author DOI 10.1186/1471-2407-14-441↗
  18. Effectiveness of combined endoscopic ultrasound-guided fine-needle aspiration biopsy and stenting in patients with suspected pancreatic cancer. First author DOI 10.1097/meg.0b013e328357cdfd↗
  19. Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine. Co-author DOI 10.1016/j.clinre.2011.02.002↗

Closest collaborators

The 25 strongest of 90 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jean‐Baptiste Bachet · 10 shared papers, 2011–2026 · strength 1.22
  2. Julien Taı̈eb · 12 shared papers, 2011–2026 · strength 1.03
  3. Pascal R. Hammel · 5 shared papers, 2021–2026 · strength 0.78
  4. David Tougeron · 5 shared papers, 2019–2025 · strength 0.65
  5. Jerome F. Cros · 3 shared papers, 2023–2026 · strength 0.58
  6. Romain Coriat · 5 shared papers, 2015–2026 · strength 0.57
  7. Olivier Bouché · 3 shared papers, 2024–2026 · strength 0.56
  8. Christophe Tournigand · 3 shared papers, 2023–2026 · strength 0.51
  9. Émilie Soularue · 4 shared papers, 2020–2025 · strength 0.48
  10. Jean–Marc Phelip · 3 shared papers, 2019–2026 · strength 0.48
  11. David Malka · 4 shared papers, 2014–2026 · strength 0.42
  12. Raëf Abdallah · 2 shared papers, 2025–2026 · strength 0.40
  13. Laëtitia Dahan · 2 shared papers, 2025–2026 · strength 0.40
  14. Louis de Mestier · 2 shared papers, 2024–2026 · strength 0.40
  15. Déwi Vernerey · 2 shared papers, 2021–2026 · strength 0.34
  16. Christophe Louvet · 2 shared papers, 2021–2026 · strength 0.34
  17. Anne‐Laure Pointet · 3 shared papers, 2019–2025 · strength 0.33
  18. Dominique Béchade · 3 shared papers, 2019–2025 · strength 0.33
  19. Simon Pernot · 3 shared papers, 2019–2025 · strength 0.33
  20. Nicolas Williet · 3 shared papers, 2019–2025 · strength 0.33
  21. Thierry André · 2 shared papers, 2016–2026 · strength 0.31
  22. Solène Doat · 2 shared papers, 2021–2024 · strength 0.28
  23. António Sá Cunha · 4 shared papers, 2015–2021 · strength 0.27
  24. Christelle de la Fouchardière · 2 shared papers, 2015–2026 · strength 0.26
  25. Daniel Pietrasz · 3 shared papers, 2015–2021 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.